Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the tre...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

WaveyMaybeDavey Jul. 19 at 6:06 PM

$LCTX https://www.linkedin.com/posts/zhonghaol_genetherapy-drugdiscovery-patientsafety-activity-7352061988178481155-SUOy?utm_medium=ios_app&rcm=ACoAAAPDZZ4B9cNdEj8qKfHLDSkdEWZ9RN_5img&utm_source=social_share_send&utm_campaign=share_via

5 · Reply

Turnerjack27 Jul. 19 at 5:20 PM

$LCTX Does anybody have the latest on the CIRM grant money? Every penny counts!

3 · Reply

JohnPDaly Jul. 19 at 2:12 PM

$LCTX Had this painting done of our fall pasture. Good investment.:-)

4 · Reply

ChasRiggs Jul. 18 at 11:33 PM

$LCTX gave everyone the playbook on today. I’ve seen it time and time again. Hopefully we bounce back Monday. Bought more.

1 · Reply

G_33 Jul. 18 at 10:49 PM

$LCTX BlackRock owns 1% of the common stock. https://x.com/tman1138pm/status/1946271833579241963?s=46&t=xlbYRxreUUYffBLqu_f5RQ

2 · Reply

z06forum Jul. 18 at 8:34 PM

$LCTX I Cannot Speak for anyone but me. My conviction is as high as it could get for a company like this. I happy I was able to Move things around in my portfolio and get in heavier at the .40 range. My avg is low .60's and I am confident we are headed to in the right direction. Keep cool and wait for things to play out.. I would rather see some Business development come in before ph3 to be honest.. Building more asset value right now leaves the one hit wonder theory behind.. Have a great weekend !!

3 · Reply

Trak2 Jul. 18 at 7:07 PM

$LCTX I get the frustration part, I’ve only owned the stock for four years, not as long as you guys. it does help when you post positive stories, It doesn’t help your health complaining about it every day. I believe in the potential, but it does get frustrating. thanks for all the valuable information. You guys post.

2 · Reply

Logic102 Jul. 18 at 6:50 PM

$LCTX Buy the silliness. We should be above $2.

1 · Reply

JohnPDaly Jul. 18 at 6:39 PM

https://stocktwits.com/news-articles/markets/equity/mesoblast-gives-positive-update-about-potential-fda-application-for-revascor/chlgT5lRb6z $LCTX Allogenic for the win.

0 · Reply

Berkshireannhathaway Jul. 18 at 5:48 PM

$LCTX just give me that damn dollar, how many time do I have to tell you. If you don’t do it by power hour, the switch is being taken away, there is no more screen time today m-tonight and you’ll be all alone. Grounded if you don’t behave…

1 · Reply

Two Biotech Stocks Poised For Big Moves On Monday

SANA

Jun 23, 2025, 7:00 AM EDT - 26 days ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 5, 2025, 8:00 AM EDT - 6 weeks ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

May 14, 2025, 8:00 AM EDT - 2 months ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 13, 2025, 5:53 PM EDT - 2 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 2 months ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 2 months ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 1, 2025, 8:00 AM EDT - 2 months ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Apr 22, 2025, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 21, 2025, 8:00 AM EDT - 3 months ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Mar 10, 2025, 8:16 PM EDT - 4 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:05 PM EDT - 4 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 4 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Feb 11, 2025, 8:00 AM EST - 5 months ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 4, 2025, 8:00 AM EST - 5 months ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Jan 27, 2025, 4:05 PM EST - 6 months ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Jan 6, 2025, 8:00 AM EST - 6 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Nov 21, 2024, 5:00 PM EST - 8 months ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 8 months ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 14, 2024, 9:39 PM EST - 8 months ago

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 8 months ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 8:00 AM EST - 9 months ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Oct 14, 2024, 8:00 AM EDT - 9 months ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Sep 25, 2024, 8:00 AM EDT - 10 months ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 18, 2024, 8:00 AM EDT - 10 months ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 10, 2024, 12:03 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 1 year ago

Lineage to Present at 2024 BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 10, 2024, 12:33 AM EDT - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Lineage Announces Changes to Board of Directors

Apr 23, 2024, 8:05 AM EDT - 1 year ago

Lineage Announces Appointment of New Board Member

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 13, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 11, 2024, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

Mar 7, 2024, 10:22 PM EST - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

Feb 13, 2024, 8:00 AM EST - 1 year ago

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Feb 9, 2024, 9:15 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

Feb 6, 2024, 9:15 AM EST - 1 year ago

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering

Jan 16, 2024, 8:00 AM EST - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS

WaveyMaybeDavey Jul. 19 at 6:06 PM

5 · Reply

Turnerjack27 Jul. 19 at 5:20 PM

$LCTX Does anybody have the latest on the CIRM grant money? Every penny counts!

3 · Reply

JohnPDaly Jul. 19 at 2:12 PM

$LCTX Had this painting done of our fall pasture. Good investment.:-)

4 · Reply

ChasRiggs Jul. 18 at 11:33 PM

$LCTX gave everyone the playbook on today. I’ve seen it time and time again. Hopefully we bounce back Monday. Bought more.

1 · Reply

G_33 Jul. 18 at 10:49 PM

$LCTX BlackRock owns 1% of the common stock. https://x.com/tman1138pm/status/1946271833579241963?s=46&t=xlbYRxreUUYffBLqu_f5RQ

2 · Reply

z06forum Jul. 18 at 8:34 PM

3 · Reply

Trak2 Jul. 18 at 7:07 PM

2 · Reply

Logic102 Jul. 18 at 6:50 PM

$LCTX Buy the silliness. We should be above $2.

1 · Reply

JohnPDaly Jul. 18 at 6:39 PM

https://stocktwits.com/news-articles/markets/equity/mesoblast-gives-positive-update-about-potential-fda-application-for-revascor/chlgT5lRb6z $LCTX Allogenic for the win.

0 · Reply

Berkshireannhathaway Jul. 18 at 5:48 PM

1 · Reply

GrumpyBull_747 Jul. 18 at 5:46 PM

$LCTX Some people here are getting discouraged. Know what you own. Stock price has made a nice move over the last month or two and is flagging nicely while the moving averages catch up.

1 · Reply

alphadog10 Jul. 18 at 4:54 PM

$LCTX

2 · Reply

alphadog10 Jul. 18 at 4:35 PM

$LCTX The best part is Shkreli follows him on X but Culley didn't follow him back. 😂

0 · Reply

alphadog10 Jul. 18 at 4:10 PM

$LCTX you'll have to excuse me men. Im stating facts of course like always but seeing SANA move like this is like a direct slap in the face. I truly hope the people running this feel it also.

1 · Reply

alphadog10 Jul. 18 at 4:03 PM

$LCTX i have to cheer for something right!!? 20 years later nothing to cheer about here. Just our limp dick fanboy ceo deleting his own posts on X. What a tone deaf idiot. i hope hes watching sana kick his ass all over the place

1 · Reply

alphadog10 Jul. 18 at 4:00 PM

$LCTX Look at the leader in cell therapy SANA making huge moves ! Wow keeps on climbing $4.72 congrats SANA holders. 👏🏽 Same amount of shares with 1 patient data and they just eclipsed a 1b market cap.

0 · Reply

JohnPDaly Jul. 18 at 3:57 PM

$LCTX A red Friday makes for a gray weekend.

2 · Reply

Logic102 Jul. 18 at 2:34 PM

$LCTX It appears that the Culley/Makary BROmance may be deepening. This FDA proclamation of Priority Vouchers is more great news for Lineage: https://stkt.co/Dnw0wbHj

1 · Reply

alphadog10 Jul. 18 at 2:09 PM

$LCTX if this guy isn’t correct then where did the post disappear to? Thats what I'd like to know

0 · Reply

alphadog10 Jul. 18 at 2:08 PM

$LCTX does anyone know what happened to this X post on culleys page? I cant seem to find it..

0 · Reply

alphadog10 Jul. 18 at 1:38 PM

$LCTX im surprised the spinal cord injury patients haven't started one yet. They've been waiting for OPC-1 since 2009. They should petition the FDA also and ask whats going on

1 · Reply

alphadog10 Jul. 18 at 1:37 PM

$LCTX who wants to start one? 😂

0 · Reply

Market Cap	226.07M
Revenue (ttm)	9.50M
Net Income (ttm)	-18.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-195.89%
Debt to Equity Ratio	0.00

Volume	1,463,200
Avg Vol	2,568,928
Day's Range	N/A - N/A
Shares Out	228.36M
Stochastic %K	11%
Beta	1.60
Analysts	Strong Sell
Price Target	$3.92